Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10991959,hepatic clearance,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],10.4,727,DB00636,Clofibrate
,10991959,apparent intrinsic clearance,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],94.1,728,DB00636,Clofibrate
,10991959,hepatic extraction ratio,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],94.1,729,DB00636,Clofibrate
,10991959,biliary excretion half-life,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),min,30.9,730,DB00636,Clofibrate
,28216581,apparent permeability,"The apparent permeability in everted sac rat intestine model was 8.73 × 10-6 cm/s in duodenum and 1.62 × 10-5 cm/s in jejunum, suggesting that Compound 1 has low permeability.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),[cm] / [s],8.73 × 10-6,1774,DB00636,Clofibrate
,28216581,apparent permeability,"The apparent permeability in everted sac rat intestine model was 8.73 × 10-6 cm/s in duodenum and 1.62 × 10-5 cm/s in jejunum, suggesting that Compound 1 has low permeability.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),[cm] / [s],1.62 × 10-5,1775,DB00636,Clofibrate
,28216581,Elimination constant,"Elimination constant after an oral administration of 50 μg/kg in Wistar rat was 1.81 h-1, absorption constant was 3.05 h-1, Cmax was 3.57 μg/mL at 0.33 h, AUC0-α was 956.54 μ/mL·h and distribution volume was 419.4 mL.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),1/[h],1.81,1776,DB00636,Clofibrate
,28216581,absorption constant,"Elimination constant after an oral administration of 50 μg/kg in Wistar rat was 1.81 h-1, absorption constant was 3.05 h-1, Cmax was 3.57 μg/mL at 0.33 h, AUC0-α was 956.54 μ/mL·h and distribution volume was 419.4 mL.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),1/[h],3.05,1777,DB00636,Clofibrate
,28216581,Cmax,"Elimination constant after an oral administration of 50 μg/kg in Wistar rat was 1.81 h-1, absorption constant was 3.05 h-1, Cmax was 3.57 μg/mL at 0.33 h, AUC0-α was 956.54 μ/mL·h and distribution volume was 419.4 mL.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),[μg] / [ml],3.57,1778,DB00636,Clofibrate
,28216581,AUC0-α,"Elimination constant after an oral administration of 50 μg/kg in Wistar rat was 1.81 h-1, absorption constant was 3.05 h-1, Cmax was 3.57 μg/mL at 0.33 h, AUC0-α was 956.54 μ/mL·h and distribution volume was 419.4 mL.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),[μ] / [h·ml],956.54,1779,DB00636,Clofibrate
,28216581,distribution volume,"Elimination constant after an oral administration of 50 μg/kg in Wistar rat was 1.81 h-1, absorption constant was 3.05 h-1, Cmax was 3.57 μg/mL at 0.33 h, AUC0-α was 956.54 μ/mL·h and distribution volume was 419.4 mL.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),ml,419.4,1780,DB00636,Clofibrate
,28216581,ke,"To IV administration at the same dose, ke was 1.21 h-1, Vd was 399.6 mL and AUC0-α was 747.81 μ/mL·h.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),1/[h],1.21,1781,DB00636,Clofibrate
,28216581,Vd,"To IV administration at the same dose, ke was 1.21 h-1, Vd was 399.6 mL and AUC0-α was 747.81 μ/mL·h.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),ml,399.6,1782,DB00636,Clofibrate
,28216581,AUC0-α,"To IV administration at the same dose, ke was 1.21 h-1, Vd was 399.6 mL and AUC0-α was 747.81 μ/mL·h.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),[μ] / [h·ml],747.81,1783,DB00636,Clofibrate
,28216581,Bioavailability,Bioavailability evaluated was 10.4%.,Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),%,10.4,1784,DB00636,Clofibrate
,28216581,half-life,"Compound 1 is metabolized to Compound 2 probably by enzymatic hydrolysis, and it showed a half-life of 9.24 h.",Biopharmaceutical Characterization and Bioavailability Study of a Tetrazole Analog of Clofibric Acid in Rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28216581/),h,9.24,1785,DB00636,Clofibrate
,7471606,plasma concentration,Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the probenecid.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,2.5,4012,DB00636,Clofibrate
,7471606,plasma concentration,Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the probenecid.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,9.05,4013,DB00636,Clofibrate
,7471606,plasma concentration,Probenecid reached an average plasma concentration of 71.3 mg/1.,Probenecid-clofibrate interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7471606/),mg,71.3,4014,DB00636,Clofibrate
,7319135,areas under the serum concentration curves,The areas under the serum concentration curves were not statistically significantly different (median of 31.3 mg .,Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319135/),mg,31.3,5791,DB00636,Clofibrate
,1133166,steady-state plasma concentration,"However, there was also a lower steady-state plasma concentration of diphenylhydantoin (2.9 plus or minus 0.6 vs.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),,2.9,11292,DB00636,Clofibrate
,1133166,plasms clearance,"6.8 plus or minus 0.6 mug/ml, P smaller than 0.001) secondary to an increase in the plasms clearance (0.048 plus or minus 0.019 vs. 0.022 plus or minus 0.006 liter/kg.h, P smaller than 0.001) in the nephrotic patients.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[l] / [h·kg],0.048,11293,DB00636,Clofibrate
,1133166,plasms clearance,"6.8 plus or minus 0.6 mug/ml, P smaller than 0.001) secondary to an increase in the plasms clearance (0.048 plus or minus 0.019 vs. 0.022 plus or minus 0.006 liter/kg.h, P smaller than 0.001) in the nephrotic patients.",Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[l] / [h·kg],0.022,11294,DB00636,Clofibrate
,1133166,absolute concentration,The net effect is no difference in the absolute concentration of unbound diphenylhydantoin in healthy individuals (0.69 plus or minus 0.05 mug/ml) and patients with the nephrotic syndrome (0.59 plus or minus 0.06 mug/ml).,Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[μg] / [ml],0.69,11295,DB00636,Clofibrate
,1133166,absolute concentration,The net effect is no difference in the absolute concentration of unbound diphenylhydantoin in healthy individuals (0.69 plus or minus 0.05 mug/ml) and patients with the nephrotic syndrome (0.59 plus or minus 0.06 mug/ml).,Pharmacokinetics of drugs in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133166/),[μg] / [ml],0.59,11296,DB00636,Clofibrate
,2039683,flow rate,"The chromatographic separation was performed on a silica gel stationary phase (Zorbax Sil) using n-hexane-chloroform-ethanol (100:10:0.75, by vol) as mobile phase [flow rate, 2 ml/min; fluorescence detection, 305/355 nm; elution order of the derivatives, (-) before (+)].",Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039683/),[ml] / [min],2,23980,DB00636,Clofibrate
,2039683,Limit of quantification,Limit of quantification was 20-25 ng/ml for plasma based on a sample volume of 0.2 ml.,Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039683/),[ng] / [ml],20-25,23981,DB00636,Clofibrate
,1208648,elimination half-life,"When plasma FFA were elevated to about 2,000 muEq/1, the CPIB elimination half-life decreased form 19.3 h in controls to 7.3 h.",Clofibrate pharmacokinetics: effect of elevation of plasma-free fatty acids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1208648/),h,19.3,27325,DB00636,Clofibrate
,1208648,elimination half-life,"When plasma FFA were elevated to about 2,000 muEq/1, the CPIB elimination half-life decreased form 19.3 h in controls to 7.3 h.",Clofibrate pharmacokinetics: effect of elevation of plasma-free fatty acids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1208648/),h,7.3,27326,DB00636,Clofibrate
,1149779,peak plasma CPIB concentration,"Peak levels were reached 3.5 hours after drug intake, the mean peak plasma CPIB concentration being 193 mug/ml.",Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149779/),[μg] / [ml],193,42821,DB00636,Clofibrate
exceeded,1149779,Absorption,Absorption of CPIB exceeded 99%.,Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149779/),%,99,42822,DB00636,Clofibrate
,1149779,t 1/2,"The decay of radioactive CPIB in plasma was not log-linear: the mean t 1/2 of the first exponential was 0.45 hours, and of the second 15.1 hours.",Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149779/),h,0.45,42823,DB00636,Clofibrate
,1149779,t 1/2,"The decay of radioactive CPIB in plasma was not log-linear: the mean t 1/2 of the first exponential was 0.45 hours, and of the second 15.1 hours.",Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149779/),h,15.1,42824,DB00636,Clofibrate
,6712867,Cmax,The Cmax in the former case was 24.0 +/- 4.6 mg l-1 as against a value of 15.2 +/- 6.9 mg l-1 in the latter (P less than 0.01).,Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6712867/),[mg] / [l],24.0,52405,DB00636,Clofibrate
,6712867,Cmax,The Cmax in the former case was 24.0 +/- 4.6 mg l-1 as against a value of 15.2 +/- 6.9 mg l-1 in the latter (P less than 0.01).,Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6712867/),[mg] / [l],15.2,52406,DB00636,Clofibrate
,9495875,clearance,The clearance of R-ibuprofen more than doubled in the clofibrate-treated group (mean +/- S.E.M.; 29.4 +/- 4.0 ml/min) as compared to control rats (13.0 +/- 1.4 ml/min; P = .003).,Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],29.4,57428,DB00636,Clofibrate
,9495875,clearance,The clearance of R-ibuprofen more than doubled in the clofibrate-treated group (mean +/- S.E.M.; 29.4 +/- 4.0 ml/min) as compared to control rats (13.0 +/- 1.4 ml/min; P = .003).,Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],13.0,57429,DB00636,Clofibrate
,9495875,clearance,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],23.2,57430,DB00636,Clofibrate
,9495875,clearance,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[ml] / [min],10.0,57431,DB00636,Clofibrate
,9495875,t1/2 inversion,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),min,8.3,57432,DB00636,Clofibrate
,9495875,t1/2 inversion,"This increase was similarly reflected in the clearance by inversion (treated, 23.2 +/- 3.2 ml/min, untreated, 10.0 +/- 1.2 ml/min; P = .003) and there was also an increase in the rate of inversion (treated, t1/2 inversion, 8.3 +/- 1.6 min; untreated, 13.9 +/- 1.4 min; P = .029).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),min,13.9,57433,DB00636,Clofibrate
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],4.42,57434,DB00636,Clofibrate
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],1.03,57435,DB00636,Clofibrate
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],1.04,57436,DB00636,Clofibrate
,9495875,volume of distribution at steady-state,"There was a significant increase in volume of distribution at steady-state (treated, 4.42 +/- 1.12 liter/kg; untreated, 1.03 +/- 0.30 liter/kg; P = .017) observed for the R-enantiomer but not the S-enantiomer (treated, 1.04 +/- 0.13 liter/kg; untreated, 1.10 +/- 0.21 liter/kg).",Effect of clofibrate on the chiral disposition of ibuprofen in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495875/),[l] / [kg],1.10,57437,DB00636,Clofibrate
,33982312,m/z,"The selected reaction monitoring transitions for CTD and clofibrate (internal standard) were m/z 128 → 85 and m/z 169 → 141, respectively.",Pharmacokinetics and tissue distribution of cantharidin after oral administration of aqueous extracts from Mylabris in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982312/),,128,71112,DB00636,Clofibrate
,33982312,m/z,"The selected reaction monitoring transitions for CTD and clofibrate (internal standard) were m/z 128 → 85 and m/z 169 → 141, respectively.",Pharmacokinetics and tissue distribution of cantharidin after oral administration of aqueous extracts from Mylabris in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982312/),,85,71113,DB00636,Clofibrate
,33982312,m/z,"The selected reaction monitoring transitions for CTD and clofibrate (internal standard) were m/z 128 → 85 and m/z 169 → 141, respectively.",Pharmacokinetics and tissue distribution of cantharidin after oral administration of aqueous extracts from Mylabris in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982312/),,169,71114,DB00636,Clofibrate
,33982312,m/z,"The selected reaction monitoring transitions for CTD and clofibrate (internal standard) were m/z 128 → 85 and m/z 169 → 141, respectively.",Pharmacokinetics and tissue distribution of cantharidin after oral administration of aqueous extracts from Mylabris in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982312/),,141,71115,DB00636,Clofibrate
,33982312,Extraction recovery,Extraction recovery ranged from 89.21 to 103.61% for CTD in rat plasma and liver and from 83.79 to 102.74% for IS in rat plasma and liver.,Pharmacokinetics and tissue distribution of cantharidin after oral administration of aqueous extracts from Mylabris in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982312/),%,89.21 to 103.61,71116,DB00636,Clofibrate
,33982312,Extraction recovery,Extraction recovery ranged from 89.21 to 103.61% for CTD in rat plasma and liver and from 83.79 to 102.74% for IS in rat plasma and liver.,Pharmacokinetics and tissue distribution of cantharidin after oral administration of aqueous extracts from Mylabris in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982312/),%,83.79 to 102.74,71117,DB00636,Clofibrate
,6105184,half-life,"The half-life of CPIB, the main active metabolite, in the serum is about 12 h in the rat, 43 +/- 9 h in the dog and 6 +/- 1 h in the baboon.","On the metabolism of clofibride, a hypolipaemic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105184/),h,12,71268,DB00636,Clofibrate
,6105184,half-life,"The half-life of CPIB, the main active metabolite, in the serum is about 12 h in the rat, 43 +/- 9 h in the dog and 6 +/- 1 h in the baboon.","On the metabolism of clofibride, a hypolipaemic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105184/),h,43,71269,DB00636,Clofibrate
,6105184,half-life,"The half-life of CPIB, the main active metabolite, in the serum is about 12 h in the rat, 43 +/- 9 h in the dog and 6 +/- 1 h in the baboon.","On the metabolism of clofibride, a hypolipaemic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105184/),h,6,71270,DB00636,Clofibrate
,6105184,half-life,The half-life of 4-chlorophenol glucuronate ether in the serum is about 4 h whereas that of HMB is about 3 h.,"On the metabolism of clofibride, a hypolipaemic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105184/),h,4,71271,DB00636,Clofibrate
,6105184,half-life,The half-life of 4-chlorophenol glucuronate ether in the serum is about 4 h whereas that of HMB is about 3 h.,"On the metabolism of clofibride, a hypolipaemic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105184/),h,3,71272,DB00636,Clofibrate
,7318880,plasma half-life,"Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7.8 +3.9 h (SD) and the plasma clearance was 0.03 +0.02 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),h,7.8,118239,DB00636,Clofibrate
,7318880,plasma clearance,"Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7.8 +3.9 h (SD) and the plasma clearance was 0.03 +0.02 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),[1] / [kg],0.03,118240,DB00636,Clofibrate
shorter,7318880,plasma half-life,"Three of the patients had a creatinine clearance greater than 40 ml/min; in them the plasma half-life was shorter, 4.6 +1.2 h, and the plasma clearance was higher, 0.06 +0.01 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),h,4.6,118241,DB00636,Clofibrate
higher,7318880,plasma clearance,"Three of the patients had a creatinine clearance greater than 40 ml/min; in them the plasma half-life was shorter, 4.6 +1.2 h, and the plasma clearance was higher, 0.06 +0.01 1/kg .",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),[1] / [kg],0.06,118242,DB00636,Clofibrate
,7318880,plasma half-life,"This patient had a plasma half-life of 20.l h, which is ten times longer than has been reported in healthy volunteers.",Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318880/),h,20.l,118243,DB00636,Clofibrate
,6595991,apparent t1/2,"At the lowest dose level (15 mg/kg), the plasma concentration-time profile appeared to follow first order kinetics, with an apparent t1/2 of 1 h; at dose levels which might be used in toxicity studies (45 and 150 mg/kg) the apparent t1/2 was longer, indicating dose-related trends by both routes of administration.",Dose-dependent pharmacokinetics of clofibric acid in the non-human primate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6595991/),h,1,122308,DB00636,Clofibrate
,2611089,apparent elimination half-life,"2. Under fasting conditions, ciprofibrate, was absorbed rapidly in subjects with normal renal function, and its apparent elimination half-life was approximately 81 h.",The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611089/),h,81,149570,DB00636,Clofibrate
,2611089,renal clearance,Both renal clearance (0.15 ml min-1) and cumulative renal excretion (less than 7% of the administered dose) were low.,The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611089/),[ml] / [min],0.15,149571,DB00636,Clofibrate
,1037251,half-life,CPIB disappeared from plasma with a mean half-life of 17.6 h.,[A quantitative gaschromatographic method for the determination of p-chlorophenoxyisobutyric acid (clofibrinic acid) in human plasma (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037251/),h,17.6,154887,DB00636,Clofibrate
,3784441,Elimination half-lives,Elimination half-lives were 17 h at start and 22 h after 12 weeks compared with 2 h in subjects with normal renal function.,Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),h,17,157951,DB00636,Clofibrate
,3784441,Elimination half-lives,Elimination half-lives were 17 h at start and 22 h after 12 weeks compared with 2 h in subjects with normal renal function.,Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),h,22,157952,DB00636,Clofibrate
,3784441,Elimination half-lives,Elimination half-lives were 17 h at start and 22 h after 12 weeks compared with 2 h in subjects with normal renal function.,Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),h,2,157953,DB00636,Clofibrate
,3784441,therapeutic serum concentration,"Dose reduction to 200 mg every 3rd day was necessary and resulted in a mean therapeutic serum concentration of 3.4 mg/l, which was similar to 3.0 mg/l of normal subjects, who received the dose optimal for lowering of lipids (200 mg 3 X/day).",Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),[mg] / [l],3.4,157954,DB00636,Clofibrate
,3784441,therapeutic serum concentration,"Dose reduction to 200 mg every 3rd day was necessary and resulted in a mean therapeutic serum concentration of 3.4 mg/l, which was similar to 3.0 mg/l of normal subjects, who received the dose optimal for lowering of lipids (200 mg 3 X/day).",Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3784441/),[mg] / [l],3.0,157955,DB00636,Clofibrate
,2869889,LD50,The LD50 of itanoxone injected i.v. in the crab Pachygrapsus marmoratus is 144 mg/kg.,"Pharmacokinetic and metabolic study of itanoxone in the crab Pachygrapsus marmoratus (Decapoda, Brachyura): comparative study with clofibric acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2869889/),[mg] / [kg],144,160353,DB00636,Clofibrate
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),min,1,200189,DB00636,Clofibrate
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),min,4,200190,DB00636,Clofibrate
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),h,1,200191,DB00636,Clofibrate
,7194058,invasion half-life,The following mean values were found: the invasion half-life is 1 h 4 min for clofibric acid and 1 h 52 min for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),min,52,200192,DB00636,Clofibrate
,7194058,maximum concentration,The maximum concentration after approximately 4 h is 22.75 micrograms/ml for clofibric acid and 6.57 micrograms/ml for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),[μg] / [ml],22.75,200193,DB00636,Clofibrate
,7194058,maximum concentration,The maximum concentration after approximately 4 h is 22.75 micrograms/ml for clofibric acid and 6.57 micrograms/ml for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),[μg] / [ml],6.57,200194,DB00636,Clofibrate
,7194058,elimination half-life,The elimination half-life is 12.12 h for clofibric and 4.33 h for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),h,12.12,200195,DB00636,Clofibrate
,7194058,elimination half-life,The elimination half-life is 12.12 h for clofibric and 4.33 h for etofylline.,"[Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194058/),h,4.33,200196,DB00636,Clofibrate
,4009437,terminal half-life,"Etofibrate, the ethylene glycol diester of clofibric and nicotinic acids, on intravenous infusion into dogs, has a terminal half-life of 2 min.","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,2,201105,DB00636,Clofibrate
,4009437,terminal half-lives,"The intermediate half-esters, the nicotinate and the clofibrate, have respective terminal half-lives of 4.6 and 1.7 min and appear fleetingly when etofibrate is administered.","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,4.6,201106,DB00636,Clofibrate
,4009437,terminal half-lives,"The intermediate half-esters, the nicotinate and the clofibrate, have respective terminal half-lives of 4.6 and 1.7 min and appear fleetingly when etofibrate is administered.","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,1.7,201107,DB00636,Clofibrate
,4009437,terminal half-life,"In contrast to the 42-h terminal half-life of clofibric acid, the other final transformation product, nicotinic acid, shows saturable or dose-dependent pharmacokinetics in dogs that conform to the Michaelis-Menten equation with a terminal half-life of 4.4 min at low concentrations (less than 6.9 microM/kg).","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),h,42,201108,DB00636,Clofibrate
,4009437,terminal half-life,"In contrast to the 42-h terminal half-life of clofibric acid, the other final transformation product, nicotinic acid, shows saturable or dose-dependent pharmacokinetics in dogs that conform to the Michaelis-Menten equation with a terminal half-life of 4.4 min at low concentrations (less than 6.9 microM/kg).","Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),min,4.4,201109,DB00636,Clofibrate
,4009437,renal clearance,Nicotinic acid is excreted 30% unchanged into urine with a renal clearance of 70 mL/min in 27-kg dogs.,"Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009437/),[ml] / [min],70,201110,DB00636,Clofibrate
,4039571,peak whole blood levels,"Mean peak whole blood levels of 11.9 micrograms/ml at 2.8 h and 35.3 micrograms/ml at 1.3 h, respectively, occurred after administration of etofibrate and nicotinic acid alone.",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],11.9,212497,DB00636,Clofibrate
,4039571,peak whole blood levels,"Mean peak whole blood levels of 11.9 micrograms/ml at 2.8 h and 35.3 micrograms/ml at 1.3 h, respectively, occurred after administration of etofibrate and nicotinic acid alone.",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],35.3,212498,DB00636,Clofibrate
,4039571,peak plasma levels,"However, mean peak plasma levels of 127.3 micrograms/ml at 3.6 h and 170.8 micrograms/ml at 2.4 h, respectively, occurred after administration of etofibrate and clofibric acid alone and were significantly different (P less than 0.01).",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],127.3,212499,DB00636,Clofibrate
,4039571,peak plasma levels,"However, mean peak plasma levels of 127.3 micrograms/ml at 3.6 h and 170.8 micrograms/ml at 2.4 h, respectively, occurred after administration of etofibrate and clofibric acid alone and were significantly different (P less than 0.01).",Bioavailability studies of etofibrate in rhesus monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),[μg] / [ml],170.8,212500,DB00636,Clofibrate
,4039571,half-lives,"The half-lives of nicotinic acid (in whole blood) and clofibric acid (in plasma) in rhesus monkeys when these drugs were administered alone were 9.9 h and 1.8 h, respectively.",Bioavailability studies of etofibrate in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),h,9.9,212501,DB00636,Clofibrate
,4039571,half-lives,"The half-lives of nicotinic acid (in whole blood) and clofibric acid (in plasma) in rhesus monkeys when these drugs were administered alone were 9.9 h and 1.8 h, respectively.",Bioavailability studies of etofibrate in rhesus monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039571/),h,1.8,212502,DB00636,Clofibrate
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],3445,230846,DB00636,Clofibrate
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],844,230847,DB00636,Clofibrate
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],4436,230848,DB00636,Clofibrate
,18670166,AUC(0-24hr),"Compared to Sprague-Dawley (SD) rats, the parent strain of NAR, 4.1-fold higher AUC(0-24hr) based on free drug concentrations (3445 versus 844 microg.hr/ml) was observed in NAR when both rats showed the same level of AUC(0-24hr) based on the total drug concentrations (4436 versus 4237microg.hr/ml).",Toxicokintic and toxicodynamic analysis of clofibrate based on free drug concentrations in nagase analbuminemia rats (NAR). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670166/),[h·μg] / [ml],4237,230849,DB00636,Clofibrate
,2815833,t1/2,"2. After oral administration of single daily doses for 7 days, the plasma elimination half-life for bezafibrate was rapid (t1/2 of 4-5 h) in comparison to ciprofibrate (t1/2 of 76 h).",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),h,4-5,237590,DB00636,Clofibrate
,2815833,t1/2,"2. After oral administration of single daily doses for 7 days, the plasma elimination half-life for bezafibrate was rapid (t1/2 of 4-5 h) in comparison to ciprofibrate (t1/2 of 76 h).",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),h,76,237591,DB00636,Clofibrate
,2815833,area under the plasma drug concentration versus time curve (AUC) 0-24,"3. The area under the plasma drug concentration versus time curve (AUC) 0-24 (micrograms.h/ml +/- SD) for bezafibrate (dose 125 mg/kg per day) was 1553 +/- 334, which was less than half the value of 3748 +/- 358 achieved by ciprofibrate (10 mg/kg per day) after 7 days.",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],1553,237592,DB00636,Clofibrate
,2815833,area under the plasma drug concentration versus time curve (AUC) 0-24,"3. The area under the plasma drug concentration versus time curve (AUC) 0-24 (micrograms.h/ml +/- SD) for bezafibrate (dose 125 mg/kg per day) was 1553 +/- 334, which was less than half the value of 3748 +/- 358 achieved by ciprofibrate (10 mg/kg per day) after 7 days.",The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],3748,237593,DB00636,Clofibrate
,2815833,AUC 0-48,The AUC 0-48 values (micrograms.h/ml +/- SD) achieved were 5124 +/- 450 for bezafibrate compared to 4207 +/- 240 for ciprofibrate.,The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],5124,237594,DB00636,Clofibrate
,2815833,AUC 0-48,The AUC 0-48 values (micrograms.h/ml +/- SD) achieved were 5124 +/- 450 for bezafibrate compared to 4207 +/- 240 for ciprofibrate.,The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815833/),[h·μg] / [ml],4207,237595,DB00636,Clofibrate
,598055,plasma half-life,"The mean plasma half-life of clofibrate was 16.7 hr and 68.4 hr in the control subjects and in the patients, respectively (P less than 0.001).",Clofibrate treatment of hyperlipidemia in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598055/),h,16.7,249507,DB00636,Clofibrate
,598055,plasma half-life,"The mean plasma half-life of clofibrate was 16.7 hr and 68.4 hr in the control subjects and in the patients, respectively (P less than 0.001).",Clofibrate treatment of hyperlipidemia in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598055/),h,68.4,249508,DB00636,Clofibrate
,989365,Peak levels,"Peak levels of radioactivity in the plasma of all three species studied were similar (20--30 mug/ml) after doses at these levels and concentrations declined thereafter with half-lives of 7--24 h in rats and dogs, and 7 h in man.","Antilipidemic drugs. Part 4: The metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/989365/),[μg] / [ml],20--30,251495,DB00636,Clofibrate
,989365,half-lives,"Peak levels of radioactivity in the plasma of all three species studied were similar (20--30 mug/ml) after doses at these levels and concentrations declined thereafter with half-lives of 7--24 h in rats and dogs, and 7 h in man.","Antilipidemic drugs. Part 4: The metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/989365/),h,7--24,251496,DB00636,Clofibrate
,989365,half-lives,"Peak levels of radioactivity in the plasma of all three species studied were similar (20--30 mug/ml) after doses at these levels and concentrations declined thereafter with half-lives of 7--24 h in rats and dogs, and 7 h in man.","Antilipidemic drugs. Part 4: The metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/989365/),h,7,251497,DB00636,Clofibrate
,915750,half-lives,"Peaks of mean concentrations of 80 +/- 13,67 +/- 16, and 64 +/- 18 microgram/ml +/- SD occurred after administration of 853 mg of clofibric acid calcium salt alone, 809 mg of clofibric acid calcium salt mixed with calcium carbonate, and 885 mg of clofibrate, respectively; mean concentrations declined from peak levels with half-lives of 15-17 hr.",Plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/915750/),h,15-17,259546,DB00636,Clofibrate
,930544,Absorption,Absorption of clofibric acid was found to be identical with that obtained with ethyl-alpha-p-chlorphenoxyisobutyrate (Clofibrate) reaching almost 100%.,[Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/930544/),%,100,261945,DB00636,Clofibrate
,930544,Urinary excretion,Urinary excretion of clofibric acid for both the combination drug and Clofibrate was 90% in 48 hours.,[Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/930544/),%,90,261946,DB00636,Clofibrate
above,7550835,terminal half-life (t1/2m),Elimination of CFA was prolonged corresponding to a terminal half-life (t1/2m) often above 100 hours and sometimes incalculable.,[Pharmacokinetics of clofibrate in jaundiced newborn infants at term]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550835/),h,100,268855,DB00636,Clofibrate
,7550835,MRTo-->50,"MRTo-->50 (h) was similar in both groups (ie 26.2 +/- 2.0 vs 25.5 +/- 1.3, respectively).",[Pharmacokinetics of clofibrate in jaundiced newborn infants at term]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550835/),h,26.2,268856,DB00636,Clofibrate
,7550835,MRTo-->50,"MRTo-->50 (h) was similar in both groups (ie 26.2 +/- 2.0 vs 25.5 +/- 1.3, respectively).",[Pharmacokinetics of clofibrate in jaundiced newborn infants at term]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550835/),h,25.5,268857,DB00636,Clofibrate
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],55.0,270674,DB00636,Clofibrate
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],66.4,270675,DB00636,Clofibrate
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],186.2,270676,DB00636,Clofibrate
,9728897,clearances,"When subjects were pretreated with clofibrate, clearances of R-ibuprofen and 13C-S-ibuprofen increased significantly from 55.0 and 66.4 ml/min to 186.2 and 106.7 ml/min (p < 0.01), respectively.",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],106.7,270677,DB00636,Clofibrate
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],36.0,270678,DB00636,Clofibrate
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],118.8,270679,DB00636,Clofibrate
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],19.0,270680,DB00636,Clofibrate
,9728897,clearance,"This increase was similarly reflected in the clearance by inversion of R-ibuprofen (control, 36.0 ml/min; treated, 118.8 ml/min; p < 0.01), as well as in the clearance by noninversion (control, 19.0 ml/min; treated, 67.4 ml/min; p < 0.01).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[ml] / [min],67.4,270681,DB00636,Clofibrate
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],19.5,270682,DB00636,Clofibrate
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],38.7,270683,DB00636,Clofibrate
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],11.8,270684,DB00636,Clofibrate
,9728897,Unbound clearance,"Unbound clearance values significantly increased for R-ibuprofen (control, 19.5 L/min; treated, 38.7 L/min) but not for 13C-S-ibuprofen (11.8 versus 10.6 L/min, respectively).",Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728897/),[l] / [min],10.6,270685,DB00636,Clofibrate
